| Gloria Jean Fader, LPN | |
|
1561 M 30, Alger, MI 48610-8538 | |
| (989) 965-5123 | |
| Not Available |
| Full Name | Gloria Jean Fader |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 1561 M 30, Alger, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659838183 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 4703065206 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Gloria Jean Fader, LPN 1561 M 30, Alger, MI 48610-8538 Ph: (989) 965-5123 | Gloria Jean Fader, LPN 1561 M 30, Alger, MI 48610-8538 Ph: (989) 965-5123 |
News Archive
For the first time, researchers at the University of Gothenburg have shown that metastases in patients with malignant melanoma gain access to the circulatory system not only through the outgrowth of new blood vessel branches, but also an alternative process in which one blood vessel divide into two parallel vessels bylongitudinal splitting.
In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand. Following a final analysis of the trial data, the Surgeon General of the U.S. Army, the trial sponsor, announced today that the prime-boost investigational vaccine regimen was safe and 31 percent effective in preventing HIV infection.
Leading design professionals came together earlier this week for the 27th annual By Design conference. By Design was developed by SFCS Architects to provide staff and industry professionals the opportunity to participate and share the latest innovations and research in the field of senior living. The conference was attended by over 250 participants.
With President Obama leading the charge against legalization of marijuana in what he calls a "new era of responsibility," a cultural change is taking place in California as more and more community activists join law enforcement officers, former drug addicts and faith-based leaders in support of the anti-marijuana cause.
Amgen today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study"). Results from these trials reinforce denosumab's consistent ability to delay the complications of bone metastases in patients with advanced cancer. These results are being presented during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago.
› Verified 5 days ago